Neutral Biocon; target of Rs 385 : Motilal Oswal

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Motilal Oswal's research report on Biocon

BIOS recently announced that its subsidiary, Biocon Biologics (BBL), has entered into a definitive agreement with Viatris to acquire its Biosimilar business for USD3.3b. The deal enhances BBL’s commercial/regulatory capabilities in developed markets and gives it the option to acquire b-Aflibercept (a potential Biosimilar asset). The valuation, based on estimates shared by the management, stands at 3.8x/3x CY22/CY23 sales and 16.5x/13.2x CY22/CY23 EBITDA. While the deal forward integrates BBL in the Biologics value chain, the valuation paid for acquiring the Viatris’ commercial infrastructure in developed markets is expensive.

Outlook

We raise our FY23E/FY24E EPS estimate by 3.4%/15% to factor in Viatris’ business. We value BIOS on a SoTP basis (valuing BBL at 30x EV/EBITDA for its 65% stake post-completion of the deal, valuing its 70.4% stake in Syngene at current market capitalization, value the Small Molecules business at 10x EV/EBITDA, and deducting a net debt of USD1.5b) to arrive at our TP of INR385/share. We remain Neutral given the limited upside from current levels.

More Info

At 17:30 Biocon was quoting at Rs 348.95, down Rs 45.20, or 11.47 percent.

It has touched an intraday high of Rs 397.00 and an intraday low of Rs 347.10.

It was trading with volumes of 476,751 shares, compared to its thirty day average of 187,660 shares, an increase of 154.05 percent.

In the previous trading session, the share closed up 5.36 percent or Rs 20.05 at Rs 394.15.

The share touched its 52-week high Rs 424.10 and 52-week low Rs 314.90 on 09 April, 2021 and 25 October, 2021, respectively.

Currently, it is trading 17.72 percent below its 52-week high and 10.81 percent above its 52-week low.

Market capitalisation stands at Rs 41,894.94 crore.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More